• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.
By KEVIN CURRAN Nov 19, 2018 | 04:23 PM EST
Stocks quotes in this article: PFE, MRK, GSK, AMGN, JNJ, LLY, TWLO

The current market conditions could bode well for drug stocks into the coming quarters should corrections continue.

Shares of Stock of the Day Pfizer (PFE) , Merck (MRK) , GlaxoSmithKline (GSK) , Amgen (AMGN) , Johnson & Johnson (JNJ) , and Eli Lilly (LLY)  all finished Monday's trading on a high note in the face of a drooping Dow Industrial Average and a plummeting NASDAQ 100.

"The market is telling us what we already know, people are scared of a recession and an escalating trade war and are therefore positioning more defensively," Action Alerts Plus analyst Zev Fima told Real Money. "People don't want to pay up for the high multiple when the cost of money is going up with Fed rate hikes and global growth possibly slowing."

The multiples assigned to many high-growth tech names is adding to selloffs as market fears foment as well.

As such, a forward-looking PE ratio of 14 assigned to a company like Pfizer becomes much more attractive than the 505 PE ratio assigned to cloud darling Twilio (TWLO) , which has marked a nearly 14% slide amid Monday's tech selloff.

Downside Demand Protection

The companies will also be buoyed because of the inelastic demand for their products.

Real Money contributor James "Rev Shark" DePorre noted this factor in his take on the stocks in his column this morning.

"In the midst of this ugly action there is one sector that is performing well. Pharmaceuticals are viewed as a safe haven because demand for drugs is typically unaffected by the economy," he wrote. "In addition, the group is well known as a safe haven and that makes it self-fulfilling to some extent."

It becomes common sense. Sick people will always need to take their medicine.

According to a study from the University of Utrecht and the World Health Organization, the pharmaceutical industry is one of the least affected industries in recession conditions.

"Although the economic recession [of 2008] affected many countries, only a few showed a substantial decline in pharmaceutical consumption," the study concluded. "The South East Asian region had the biggest increase in pharmaceutical consumption (+28% in Q4 09) and the American region had the smallest increase (+12% in Q4 09)."

Only high income, European countries showed marked decreases amid the economic downturn.

To be sure, a potential price crackdown in response to moves like Pfizer's choice to raise prices on Friday could throw the recession-proof thesis into a tizzy.

Until that comes, the port-in-a-storm status of pharmaceutical stocks is likely to remain steadfast.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

Jim Cramer and the AAP team hold positions in Amgen and Johnson & Johnson for their Action Alerts PLUS Charitable Trust Portfolio . Want to be alerted before Cramer buys or sells AMGN or JNJ? Learn more now.

TAGS: Economic Data | Investing | Stocks | Value Investing | Pharmaceuticals | Technology | Stock of the Day

More from Stocks

Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week

Bob Lang
Feb 28, 2021 10:30 AM EST

These names are displaying both quantitative and technical deterioration.

Jim Cramer: What History Tells Us About Bond-Rate Scares Like This

Jim Cramer
Feb 27, 2021 2:01 PM EST

We could have some real pain ahead for some stocks. Five different kinds.

Navigating a Market Correction

James "Rev Shark" DePorre
Feb 27, 2021 10:00 AM EST

The most critical factor in long-term market success is the ability to effectively navigate market corrections.

Corrective Action Produces Fading Confidence and Technical Damage

James "Rev Shark" DePorre
Feb 26, 2021 5:08 PM EST

It's dangerous to have too much exposure now, but the potential for a good recovery is there once interest rate issues are digested.

I'm Intrigued by the Recent Pullback in Aurora Mobile

Timothy Collins
Feb 26, 2021 3:30 PM EST

While the Chinese company is still not profitable, it is cash flow positive.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login